Annual balance sheet for Neurogene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 142 | 96.4 | 197 | 312 | 269 |
| Net Total Receivables | — | — | — | 0.648 | 0.46 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 144 | 99.1 | 200 | 316 | 272 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 17.2 | 15.9 | 21 | 18.5 | 15.5 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 163 | 116 | 223 | 336 | 289 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.64 | 11.1 | 23 | 15.2 | 16.4 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 20.4 | 21.6 | 36.5 | 25.4 | 23.7 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 143 | 94.3 | 186 | 310 | 265 |
| Total Liabilities & Shareholders' Equity | 163 | 116 | 223 | 336 | 289 |
| Total Common Shares Outstanding |